Progen Co., Ltd. (XKON: 296160)

Market Cap	77.75B
Revenue	n/a
Net Income	n/a
Shares Out	11.55M
EPS	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,365
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	2,465.00 - 9,380.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Progen

Progen Co., Ltd., a biotechnology company, engages in platform-based drug discovery and development activities. The company’s NTIG platform technology is used for the development of anti-cancer and immune disease treatments. It develops PG-102 for the treatment of obesity with T2DM to control blood sugar, improve metabolic function, and reduce weight in the gastrointestinal tract and adipocytes. The company was founded in 1998 and is based in Seoul, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Country: South Korea
• Stock Exchange: Korea New Exchange
• Ticker Symbol: 296160